Phagos focuses on addressing antimicrobial resistance through the development of bacteriophage-based treatments. The company offers customizable drugs that use the evolutionary potential of bacteriophages to target and eliminate resistant bacteria. Serving the healthcare sector, Phagos aims to provide sustainable, precision alternatives to traditional antibiotics for life-threatening infections.
This new model allows for continually updated phage formulations to combat resistance to antibiotics and could serve as a blueprint for global adoption.
Antimicrobial resistance is set to cause 10 million annual deaths by 2050. Bacteriophage therapy can help fill the void left by a lack of new antibiotics.
